07:00 , May 18, 2015 |  BC Week In Review  |  Company News

San Raffaele, MolMed deal

MolMed exercised an option to purchase a chimeric antigen receptor (CAR)- splice variant v6 of CD44 (CD44v6) from San Raffaele. MolMed said the compound has applications in hematological and solid tumors. The companies could not...
02:20 , Oct 9, 2014 |  BC Extra  |  Company News

Deal-maker Max Link passes away

Max Link, chairman of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Celsion Corp. (NASDAQ:CLSN) and CytRx Corp. (NASDAQ:CYTR) died on Oct. 5. Alexion said Link, who was 74, died unexpectedly while traveling on business. Link had served on...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Igen, Boehringer Mannheim GmbH deal

IGEN received a $6 million advance payment on 1997 royalties from partner Boehringer Mannheim. The payments arise from sales of the pharma company's Elecsys series of immunodiagnostics based on IGEN's Origen technology. Origen provides uniform...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Protovir human antibody targeted to cytomegalovirus data

PDLI announced results of Phase II testing in 179 people, with a preliminary analysis showing lower incidence of infection, death, or relapse of disease (the primary end points of the trial). The difference was statistically...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Technical Chemicals, Boehringer Mannheim Argentina SACIeI deal

Boehringer Mannheim will exclusively distribute TCPI's diagnostic tests in South and Central America, Mexico, and some Caribbean Islands, guaranteeing distribution of $50 million over 10 years in tests for infectious diseases, drugs of abuse and...
08:00 , Feb 7, 2011 |  BioCentury  |  Finance

Savient reloads to go it alone

Savient Pharmaceuticals Inc. traded up last week after raising $230 million in a bumped up offering of convertible debt. The deal removed the financing overhang that had dragged down the shares after the company failed...
08:00 , Feb 7, 2011 |  BioCentury  |  Finance

BioNet's Scil Set

BioNet's Scil set Scil Proteins GmbH has been funded by a single investor - BioNet Holding GmbH - for over 10 years. But last week was the first time the company announced a financing, raising...
08:00 , Mar 27, 2006 |  BioCentury  |  Product Development

Removing toxicity

Liver toxicity or unmanageable pharmacokinetics have killed a lot of drugs over the years. But with this week's announcement of Phase I safety data for a nucleotide reverse transcriptase inhibitor that had been shelved due...
07:00 , Oct 17, 2005 |  BC Week In Review  |  Company News

febit biotech GmbH board of directors update

febit biotech GmbH , Heidelberg, Germany   Business: Microarrays   Appointed: Gerald Moller, former president and CEO at Boehringer Mannheim GmbH; Michael Kranich, CEO of DH-Capital GmbH & Co.; Christof Hettich, a company consultant; and...
07:00 , Jul 28, 2003 |  BC Week In Review  |  Company News

Igen, Roche deal

ROCZ will acquire IGEN for $1.3 billion in cash plus stock in a newly formed spinoff. As a result of the deal, ROCZ has secured rights to IGEN's Origen electrochemiluminescence technology used in its Elecsys...